Available susceptibility tests

VABOMERE® (meropenem and vaborbactam) is available for manual, automated, and semi-automated susceptibility testing.

The following susceptibility tests are approved for meropenem and vaborbactam:

Automated testing

NOW AVAILABLE
bioMérieux VITEK® 2 Gram-negative Susceptibility Panel

Ordering Information

NOW AVAILABLE
bioMérieux VITEK® 2 Gram-negative Susceptibility Panel

Ordering Information

  • Meropenem/vaborbactam is available for the VITEK 2 systems (Note: Version 9 VITEK 2 software required)
  • The VITEK 2 Gram-negative susceptibility panel is intended for use with the VITEK 2 systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant aerobic Gram-negative bacilli to antimicrobial agents when used as instructed
  • Refer to VITEK 2 AST panel package insert for FDA indications for use when testing meropenem/vaborbactam with VITEK 2 Systems

For more information, contact your local bioMérieux representative or visit go.biomerieux.com/vitek. To place and track orders online, visit biomerieuxDIRECT.com or call 1-800-682-2666.

 

Beckman Coulter MicroScan® MIC Panels

Ordering Information

Beckman Coulter MicroScan® MIC Panels

Ordering Information

  • Meropenem/vaborbactam is available for MicroScan manual, autoSCAN®-4 and WalkAway® instrument systems testing
  • The MicroScan MIC Panel contains 30 clinically relevant antimicrobial tests designed to reduce offline testing and improve lab workflow for multi-drug resistant organisms

For more information, contact your local Beckman Coulter Microbiology representative, visit beckmancoulter.com or to order call (800) 526-3821.

<p><br></p>Automated testing

BD Phoenix™ Emerge™ gram-negative susceptibility panels from Becton Dickinson

Ordering Information

BD Phoenix™ Emerge™ gram-negative susceptibility panels from Becton Dickinson

Ordering Information

  • The BD Emerge™, combination, and AST only panels are intended for use on the BD Phoenix™ identification and susceptibility testing instruments in clinical laboratories as an in vitro diagnostic test to determine the susceptibility to select aerobic gram-negative bacilli to antimicrobial agents as instructed by the BD Phoenix™ labeling
  • For in vitro diagnostic use only. Observe approved biohazard precautions and aseptic techniques. This product is to be used only by adequately trained and qualified laboratory personnel. Sterilize all biohazard waste before disposal
  • Laboratories will need to ensure the BD Phoenix™ instrument is configured to match the panel type. For additional questions, contact BD at 800-638-8663

For more information, contact your local BD Diagnostic Account Representative or visit
www.bd.com/en-us/offerings/capabilities/microbiology-solutions/identification-and-susceptibility-testing.

Manual and semi-automated testing

Manual and semi-automated testing

ETEST® available for automated testing from bioMérieux

Ordering Information

ETEST® available for automated testing from bioMérieux

Ordering Information

*Meropenem concentration 0.004-64 μg/mL-vaborbactam fixed concentration 8 μg/mL.

For more information, contact your local bioMérieux Inc. representative or call customer service at 800-682-2666 or visit www.biomerieux-usa.com/ETESTMEV.

To place an order, visit: www.biomerieuxDIRECT.com.

MIC Test Strip available from Liofilchem®

Ordering Information

MIC Test Strip available from Liofilchem®

Ordering Information

*Meropenem is a gradient in the MIC Strip: 0.016-256 μg/mL; vaborbactam is at fixed concentration along the strip.

  • US customers can place an order by phone: 781-902-0312 or e-mail: orders@liofilchem.us.
  • MTS strips are also available from Fisher Scientific: Catalog #22-777-842 (10/PK), #22-777-840 (30/PK), and #22-777-841 (100/PK).

For more information, contact liofilchem@liofilchem.net.

Susceptibility Disk from Hardy Diagnostics

Ordering Information

Susceptibility Disk from Hardy Diagnostics

Ordering Information

  • Disks are clearly marked on both sides with letters and numbers designating the agent and the drug content
  • The cartridges are for use in single-disk dispensers or multiplace dispensers and compatible with dispensers such as BBL™

To order, visit hardydiagnostics.com or call 1-800-266-2222.

Thermo Scientific™ Oxoid Disk and Sensititre™ MIC plates from Thermo Fisher Scientific

Ordering Information

Thermo Scientific™ Oxoid Disk and Sensititre™ MIC plates from Thermo Fisher Scientific

Ordering Information

  • Meropenem and vaborbactam is available for disk diffusion testing using Oxoid™ disks and on Sensititre™ panels for manual and fully automated testing

For more information, contact your local Thermo Fisher Scientific Microbiology representative at microbiology@thermofisher.com or visit thermofisher.com/AST.

 

FDA-recognized antimicrobial susceptibility test interpretive criteria for meropenem and vaborbactam

For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

Ordering and billing

INDICATION AND USAGE

VABOMERE® (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE® and other antibacterial drugs, VABOMERE® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

IMPORTANT SAFETY INFORMATION

Contraindications

VABOMERE® is contraindicated in patients with known hypersensitivity to any components of VABOMERE® (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.

Warnings and Precautions

  • Hypersensitivity reactions were reported in patients treated with VABOMERE® in the clinical trials. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving therapy with beta-lactam antibacterial drugs. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another beta-lactam antibacterial drug. If an allergic reaction to VABOMERE® occurs, discontinue the drug immediately.
  • Seizures and other adverse Central Nervous System (CNS) experiences have been reported during treatment with meropenem, which is a component of VABOMERE®. Close adherence to the recommended dosage regimens is urged, especially in patients with known factors that predispose to convulsive activity.
  • Rhabdomyolysis has been reported with the use of meropenem, a component of VABOMERE® If signs or symptoms of rhabdomyolysis such as muscle pain, tenderness or weakness, dark urine, or elevated creatine phosphokinase are observed, discontinue VABOMERE and initiate appropriate therapy.
  • Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including VABOMERE®, and may range in severity from mild diarrhea to fatal colitis. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued.
  • The concomitant use of VABOMERE® and valproic acid or divalproex sodium is generally not recommended. Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. If administration of VABOMERE® is necessary, consider supplemental anticonvulsant therapy.
  • In patients with renal impairment, thrombocytopenia has been observed in patients treated with meropenem, but no clinical bleeding has been reported.
  • Alert patients receiving VABOMERE® on an outpatient basis regarding adverse reactions such as seizures, delirium, headaches and/or paresthesias that could interfere with mental alertness and/or cause motor impairment.
  • Prescribing VABOMERE® in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of drug-resistant bacteria.
  • As with other antibacterial drugs, prolonged use of VABOMERE® may result in overgrowth of nonsusceptible organisms.

Adverse Reactions

The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE® were headache, phlebitis/infusion site reactions, and diarrhea.

Please see full Prescribing Information.
Important Safety Information

INDICATION AND USAGE

VABOMERE® (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.


Contraindications

VABOMERE® is contraindicated in patients with known hypersensitivity to any components of VABOMERE® (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.